1 – 24 of 24
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Analytical performance of aPROMISE : automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting
(
- Contribution to journal › Article
-
Mark
Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer
(
- Contribution to journal › Article
- 2021
-
Mark
A retrospective study assessing the accuracy of [18F]–fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection
(
- Contribution to journal › Article
-
Mark
Two-Step Acoustophoresis Separation of Live Tumor Cells from Whole Blood
(
- Contribution to journal › Article
- 2020
-
Mark
Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients
(
- Contribution to journal › Article
- 2018
-
Mark
Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial
(
- Contribution to journal › Article
- 2017
-
Mark
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Quantitative Imaging-Biomarker in Prostate Cancer. Validation of Automated Bone Scan Index in the Context of Radiographic Disease Progression in Metastatic Castration Resistant Prostate Cancer
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Cartilage oligomeric matrix protein promotes prostate cancer progression by enhancing invasion and disrupting intracellular calcium homeostasis
(
- Contribution to journal › Article
-
Mark
Reply: A Common Mistake in Assessing the Diagnostic Value of a Test: Failure to Account for Statistical and Methodologic Issues
(
- Contribution to journal › Letter
-
Mark
Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Analytical Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize the Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer : A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice
(
- Contribution to journal › Article
-
Mark
A preanalytic validation study of automated bone scan index : Effect on accuracy and reproducibility due to the procedural variabilities in bone scan image acquisition
(
- Contribution to journal › Article
-
Mark
Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections
(
- Contribution to journal › Article
-
Mark
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
(
- Contribution to journal › Article
- 2015
-
Mark
Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
(
- Contribution to journal › Article
- 2014
-
Mark
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival
(
- Contribution to journal › Article
- 2011
-
Mark
TMPRSS2-ERG Status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
(
- Contribution to journal › Article
- 2009
-
Mark
Circulating prostate tumor cells detected by Reverse transcription-PCR in men with localized or castration-refractory prostate cancer : Concordance with CellSearch assay and association with bone metastases and with survival
(
- Contribution to journal › Article
-
Mark
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer
(
- Contribution to journal › Article
- 2007
-
Mark
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
(
- Contribution to journal › Article